Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37828724)

  • 21. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
    Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
    Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis.
    Lou J; Hao Y; Lin K; Lyu Y; Chen M; Wang H; Zou D; Jiang X; Wang R; Jin D; Lam EW; Shao S; Liu Q; Yan J; Wang X; Chen P; Zhang B; Jin B
    Mol Cancer; 2020 Sep; 19(1):138. PubMed ID: 32894144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
    Salphati L; Alicke B; Heffron TP; Shahidi-Latham S; Nishimura M; Cao T; Carano RA; Cheong J; Greve J; Koeppen H; Lau S; Lee LB; Nannini-Pepe M; Pang J; Plise EG; Quiason C; Rangell L; Zhang X; Gould SE; Phillips HS; Olivero AG
    Drug Metab Dispos; 2016 Dec; 44(12):1881-1889. PubMed ID: 27638506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.
    Shchors K; Persson AI; Rostker F; Tihan T; Lyubynska N; Li N; Swigart LB; Berger MS; Hanahan D; Weiss WA; Evan GI
    Proc Natl Acad Sci U S A; 2013 Apr; 110(16):E1480-9. PubMed ID: 23542378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.
    Talele S; Zhang W; Chen J; Gupta SK; Burgenske DM; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2022 Oct; 383(1):91-102. PubMed ID: 36137710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
    Durant ST; Zheng L; Wang Y; Chen K; Zhang L; Zhang T; Yang Z; Riches L; Trinidad AG; Fok JHL; Hunt T; Pike KG; Wilson J; Smith A; Colclough N; Reddy VP; Sykes A; Janefeldt A; Johnström P; Varnäs K; Takano A; Ling S; Orme J; Stott J; Roberts C; Barrett I; Jones G; Roudier M; Pierce A; Allen J; Kahn J; Sule A; Karlin J; Cronin A; Chapman M; Valerie K; Illingworth R; Pass M
    Sci Adv; 2018 Jun; 4(6):eaat1719. PubMed ID: 29938225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice.
    Qin H; Jiang Y; Zhang J; Deng C; Zhong Z
    Mol Pharm; 2019 Aug; 16(8):3711-3719. PubMed ID: 31299161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.
    Burton EC; Lamborn KR; Forsyth P; Scott J; O'Campo J; Uyehara-Lock J; Prados M; Berger M; Passe S; Uhm J; O'Neill BP; Jenkins RB; Aldape KD
    Clin Cancer Res; 2002 Jan; 8(1):180-7. PubMed ID: 11801556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1.
    Danovi D; Folarin A; Gogolok S; Ender C; Elbatsh AM; Engström PG; Stricker SH; Gagrica S; Georgian A; Yu D; U KP; Harvey KJ; Ferretti P; Paddison PJ; Preston JE; Abbott NJ; Bertone P; Smith A; Pollard SM
    PLoS One; 2013; 8(10):e77053. PubMed ID: 24204733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy.
    Zou Y; Wang Y; Xu S; Liu Y; Yin J; Lovejoy DB; Zheng M; Liang XJ; Park JB; Efremov YM; Ulasov I; Shi B
    Adv Mater; 2022 Aug; 34(33):e2203958. PubMed ID: 35738390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
    Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
    Kim SS; Rait A; Kim E; Pirollo KF; Nishida M; Farkas N; Dagata JA; Chang EH
    ACS Nano; 2014 Jun; 8(6):5494-514. PubMed ID: 24811110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
    Liu M; Li C; Pazgier M; Li C; Mao Y; Lv Y; Gu B; Wei G; Yuan W; Zhan C; Lu WY; Lu W
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14321-6. PubMed ID: 20660730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.
    Mohammad RM; Wu J; Azmi AS; Aboukameel A; Sosin A; Wu S; Yang D; Wang S; Al-Katib AM
    Mol Cancer; 2009 Dec; 8():115. PubMed ID: 19958544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors.
    Zhang W; Oh JH; Zhang W; Rathi S; Larson JD; Wechsler-Reya RJ; Sirianni RW; Elmquist WF
    J Pharmacol Exp Ther; 2023 Dec; 387(3):315-327. PubMed ID: 37827699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.
    Fan X; Wang Y; Song J; Wu H; Yang M; Lu L; Weng X; Liu L; Nie G
    Cancer Biol Ther; 2019; 20(10):1328-1336. PubMed ID: 31311404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.